Humacyte, Inc. (NASDAQ:HUMA) Q1 2024 Earnings Conference Call May 10, 2024 8:00 AM ET

Company Participants

Tom Johnson - Investor Relations, LifeSci Advisors
Laura Niklason - Founder, President, Chief Executive Officer
Dale Sander - Chief Financial Officer, Chief Corporate Development Officer, Treasurer
Heather Prichard - Chief Operating Officer

Conference Call Participants

Ryan Zimmerman - BTIG
Kristen Kluska - Cantor Fitzgerald
Bruce Jackson - The Benchmark Company
Josh Jennings - TD Cowen

Operator

Good morning, ladies and gentlemen, and welcome to the Humacyte First Quarter 2024 Results Conference Call. Currently all participants are in a listen-only mode. Later we will conduct a question-and-answer session and instructions will follow at that time. As a reminder, this conference call is being recorded.

I'll now turn the call over to Tom Johnson with LifeSci Advisors. Please go ahead.

Tom Johnson

Thank you, operator. Before we proceed with the call, I would like to remind everyone that certain statements made during this call are forward-looking statements under U.S. federal securities law. These statements are subject to risks and uncertainties that could cause actual results to differ materially from historical experience or present expectations. Additional information concerning factors that could cause actual results to differ from statements made on this call is contained in our periodic reports filed with the SEC.

The forward-looking statements made during this call speak only as of the date hereof, and the company undertakes no obligation to update or revise the forward-looking statements, except as required by law. Information presented on this call is contained in the press release we issued this morning and on our Form 10-Q, which, after filing, may be accessible from the Investor page of the Humacyte website.

Joining me on today's call from Humacyte are Dr. Laura Niklason, President and Chief Executive Officer; Dale Sander, Chief Financial Officer and Chief Corporate Development Officer; Dr. Heather Prichard, Chief Operating Officer. Dr. Niklason will provide a summary of the company's progress during the year and recent weeks, and Dale will review the company's financial results for the quarter ended March 31, 2024. Following their prepared remarks, the management team will be available for your questions.

I will now turn over the call to Dr. Niklason.

Laura Niklason

Thank you, Tom. Good morning, everyone, and thank you for joining us for our first quarter 2024 financial results and business update call. The start of 2024 has been highly productive for Humacyte. Notably, the FDA accepted our Biologics License Application for the HAV in the vascular trauma indication in February of this year. The HAV was granted Priority Review by the FDA with a PDUFA date set for August 10, 2024. The entire Humacyte team has been actively engaged in commercial readiness activities to support our anticipated U.S. market launch.